论文部分内容阅读
诱导性多潜能干细胞,即iPS细胞,是近年来干细胞领域最令人瞩目的一项新的干细胞制造技术,这个技术通过特定的基因组合与转染可以将已分化的体细胞诱导重编程为未分化的多能细胞。与胚胎干细胞(ES)不同,iPS细胞的制造不需要胚胎组织,也不涉及伦理学问题,更重要的是制备iPS细胞可以采用病人自己的体细胞制备,避免免疫排斥反应,并且来源广泛,因此给再生医学实践于临床带来了新的曙光。目前,iPS的研究尚处于初级阶段,本文就iPS的研究现状与已有在临床应用相关的实验报道作以综述。
Inducible pluripotent stem cells, iPS cells, are one of the most remarkable new stem cell manufacturing technologies in the field of stem cells in recent years. This technology can induce the reprogramming of differentiated somatic cells to be non-specific through gene assembly and transfection Differentiated pluripotent cells. Unlike embryonic stem cells (ES), iPS cells are made without the need for embryonic tissue and do not involve ethical issues, and more importantly, iPS cells can be prepared using the patient’s own somatic cells to avoid immune rejection and are widely available To regenerative medicine practice in the clinic has brought a new dawn. Currently, iPS research is still in its infancy, this article reviews the status quo of iPS and the existing clinical reports related to clinical trials are reviewed.